Palisade Bio, Inc.
PALI
NASDAQ·Healthcare·Biotechnology·Mkt cap $347.2M
$2.00
▼ -5.21%
P/E
-20.00
Mkt Cap
$347.2M
52-Wk Range
$0.53–$2.86
52-Week Range
$0.53 - $2.86
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 202.1% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
No bull reasons captured for this rating yet.
Bear Case
1 risk
- Above-average volatility (beta 1.5).
Growth
Stable outlook
Value
Deep value opportunity - significant discount to sector peers
Momentum
Weak
-5.7% over 3m
Quality
Excellent
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying PALI right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 9, 2026
AUG 10, 2026
Reported EPS of -$0.05 vs -$0.05 consensus (+4.3% surprise). Revenue of $500.0K vs $500.0K expected (0.0%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+4.3%
Revenue trend · last 2Q
—
—
Q1 26
Q2 26
$0
$0
Margins · last 2Q
No margin history available.
Wall Street consensus
1 analyst · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Oppenheimer · Jul 23, 2026
vs Industry
How PALI stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.